Next Article in Journal
What Is a Clinically Meaningful Survival Benefit in Refractory Metastatic Colorectal Cancer?
Previous Article in Journal
Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 2
10.3747/co.26.4731
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology †

by
S. Yip
1,*,
A. Christofides
2,
S. Banerji
3,
M.R. Downes
4,
I. Izevbaye
5,
B. Lo
6,
A. MacMillan
7,
J. McCuaig
8,
T. Stockley
9,
G.M. Yousef
10 and
A. Spatz
11
1
Cancer Genetics and Genomics Lab, BC Cancer, Vancouver, BC, Canada
2
Impact Medicom Inc., Toronto, ON, Canada
3
Department of Medical Oncology, CancerCare Manitoba, Winnipeg, MB, Canada
4
Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
5
Division of Molecular Pathology, Laboratory Medicine and Pathology, University of Alberta Hospital, Edmonton, AB, Canada
6
Molecular Diagnostics, The Ottawa Hospital, Ottawa, ON, Canada
7
Provincial Medical Genetics Program, St. John’s, NL, Canada
8
Princess Margaret Cancer Centre, Toronto, ON, Canada
9
Department of Laboratory Medicine and Pathobiology, University of Toronto and University Health Network, Toronto, ON, Canada
10
Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada
11
Departments of Pathology and Oncology, McGill University, McGill University Health Centre and Lady Davis Institute, Montreal, QC, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
†
This guideline has been endorsed by the Canadian Association of Genetic Counsellors and the Canadian Association of Pathologists/ Association canadienne des pathologistes.
Curr. Oncol. 2019, 26(2), 241-254; https://doi.org/10.3747/co.26.4731
Submission received: 2 January 2019 / Revised: 2 February 2019 / Accepted: 2 March 2019 / Published: 1 April 2019

Abstract

Rapid advancements in next-generation sequencing (NGS) technology have created an unprecedented opportunity to decipher the molecular profile of tumours to more effectively prevent, diagnose, and treat cancer. Oncologists now have the option to order molecular tests that can guide treatment decisions. However, to date, most oncologists have received limited training in genomics, and they are now faced with the challenge of understanding how such tests and their interpretation align with patient management. Guidance on how to effectively use NGS technology is therefore needed to aid oncologists in applying the results of genomic tests. The Canadian guideline presented here describes best practices and unmet needs related to ngs-based testing for somatic variants in oncology, including clinical application, assay and sample selection, bioinformatics and interpretation of reports performed by laboratories, patient communication, and clinical trials.
Keywords: next-generation sequencing; somatic variants; oncologists; sequencing; molecular genomics; pathology; guidelines next-generation sequencing; somatic variants; oncologists; sequencing; molecular genomics; pathology; guidelines

Share and Cite

MDPI and ACS Style

Yip, S.; Christofides, A.; Banerji, S.; Downes, M.R.; Izevbaye, I.; Lo, B.; MacMillan, A.; McCuaig, J.; Stockley, T.; Yousef, G.M.; et al. A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Curr. Oncol. 2019, 26, 241-254. https://doi.org/10.3747/co.26.4731

AMA Style

Yip S, Christofides A, Banerji S, Downes MR, Izevbaye I, Lo B, MacMillan A, McCuaig J, Stockley T, Yousef GM, et al. A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Current Oncology. 2019; 26(2):241-254. https://doi.org/10.3747/co.26.4731

Chicago/Turabian Style

Yip, S., A. Christofides, S. Banerji, M.R. Downes, I. Izevbaye, B. Lo, A. MacMillan, J. McCuaig, T. Stockley, G.M. Yousef, and et al. 2019. "A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology" Current Oncology 26, no. 2: 241-254. https://doi.org/10.3747/co.26.4731

APA Style

Yip, S., Christofides, A., Banerji, S., Downes, M. R., Izevbaye, I., Lo, B., MacMillan, A., McCuaig, J., Stockley, T., Yousef, G. M., & Spatz, A. (2019). A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Current Oncology, 26(2), 241-254. https://doi.org/10.3747/co.26.4731

Article Metrics

Back to TopTop